Explore Stanford technologies available for licensing:

Researchers at Stanford have developed anti-idiotypic antibodies that reverse anti-CD3 monoclonal antibody therapy, giving clinicians control over the depth and timing of T cell depletion before adoptive cell therapy.

Researchers at Stanford have developed a novel multi-specific antibody construct that precisely targets and eliminates diseased blood stem cells, offering a less toxic alternative to the chemotherapy and radiation currently used to prepare patients for stem cell transplantatio

Researchers at Stanford University have discovered that donor-specific anti-HLA antibodies can be used to detect and treat graft-versus-host disease (GVHD) in transplant recipients after allogenic transplantation.

Stanford researchers have engineered hematopoietic stem cells to provide long-term secretion of chosen therapeutic antibodies, eliminating the need of repeated dosing for delivery.

Researchers at Stanford have developed a method of preventing Graft versus Host Disease (GVHD) by inhibiting a specific immune receptor. GVHD is a major debilitating complication of transplantation.